Skip to contentH
Halozyme Therapeutics, Inc.
H
HALOHalozyme Therapeutics, Inc. Q4 2020 · 10-K
Revenue$121.70M$121.70M+126.8% vs Q4 2019 Net Income$73.16M$73.16MN/M vs Q4 2019 EPS Diluted$0.50$0.50N/M vs Q4 2019 Gross Profit$6,183,000+2.9% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Halozyme Therapeutics, Inc. · CIK 1159036 · Engraved from SEC EDGAR
derived
Operating Cash Flowderived$50,920,000N/M Free Cash Flowderived$49,221,000N/M Margins · derivedGross margin5.1%−6.1 pt vs Q4 2019
Operating margin63.8%+123.5 pt vs Q4 2019
Net margin60.1%+124.2 pt vs Q4 2019
ended Dec 31, 2020 · filed Feb 23, 2021 · 54 d after period end